Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte Dreno

Showing results (201-210 of 213) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2022
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell CarcinomaAndrey A Yurchenko, Oltin T Pop, Meriem Ighilahriz, et al.
Cell Reports. Medicine|March 19, 2025
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanomaTine J Monberg, Santeri A Pakola, Benedetta Albieri, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes)Lidija Kandolf, Ketty Peris, Josep Malvehy, et al.
The New England Journal of Medicine|June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. TreatmentAlexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023Alexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2023
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023Alexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026Alexander J Stratigos, Clio Dessinioti, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026Alexander J Stratigos, Clio Dessinioti, Claus Garbe, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Pageof 22

Showing results (201-210 of 213) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2022
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell CarcinomaAndrey A Yurchenko, Oltin T Pop, Meriem Ighilahriz, et al.
Cell Reports. Medicine|March 19, 2025
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanomaTine J Monberg, Santeri A Pakola, Benedetta Albieri, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes)Lidija Kandolf, Ketty Peris, Josep Malvehy, et al.
The New England Journal of Medicine|June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. TreatmentAlexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023Alexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2023
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023Alexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026Alexander J Stratigos, Clio Dessinioti, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026Alexander J Stratigos, Clio Dessinioti, Claus Garbe, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Pageof 22